Phytochemical evaluation and clinical effect of Syzygium aromaticum in comparison with the control group on reducing depression in depressive patients: a triple-blind randomized clinical trial
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
Comparison of changes in the overall score of the Hamilton Depression Inventory and the change in disease severity score and the overall progress score in the General Clinical Statement Questionnaire in patients with major depressive disorder receiving standard treatment with clove and receiving standard treatment with placebo
Comparison of changes in the overall score of the Hamilton Depression Inventory and the change in disease severity score and the overall progress score in the General Clinical Statement Questionnaire in patients with major depressive disorder or bipolar disorder in the depressive episode receiving standard treatment with clove and receiving standard treatment with placebo
Comparison of changes in the overall score of the Hamilton Depression Inventory and the change in disease severity score and the overall progress score in the General Clinical Statement Questionnaire in patients with major depressive disorder or bipolar disorder in the depressive episode receiving standard treatment with clove and receiving standard treatment with placebo
مقایسه میزان تغییر در نمره کلی پرسشنامه افسردگی همیلتون در بیماران با اختلال افسردگی عمده گیرنده درمان استاندارد به همراه گیاه میخک و گیرنده درمان استاندارد به همراه دارونما
مقایسه میزان تغییر در نمره کلی پرسشنامه افسردگی همیلتون در بیماران با اختلال افسردگی عمده و یا دوقطبی در فاز افسردگی گیرنده درمان استاندارد به همراه گیاه میخک و گیرنده درمان استاندارد به همراه دارونما
مقایسه میزان تغییر در نمره کلی پرسشنامه افسردگی همیلتون در بیماران با اختلال افسردگی عمده و یا دوقطبی در فاز افسردگی گیرنده درمان استاندارد به همراه گیاه میخک و گیرنده درمان استاندارد به همراه دارونما
Inclusion criteria: mild to moderate major depressive disorder with the duration of the disease episode between 1 week to 2 years;
Exclusion criteria: severe major depressive disorder; the existence of psychotic symptoms; Anxiety disorders.
Inclusion criteria: A patient aged 16 to 85 years with major depressive disorder or bipolar disorder in the depressive episode;
Exclusion criteria: the existence of psychotic symptoms; Anxiety disorders.
Inclusion criteria: mildA patient aged 16 to moderate85 years with major depressive disorder withor bipolar disorder in the duration of the diseasedepressive episode between 1 week to 2 years; Exclusion criteria: severe major depressive disorder; the existence of psychotic symptoms; Anxiety disorders.
شرایط ورود: اختلال افسردگی عمده خفیف تا متوسط با حداقل طول اپیزود بیماری ۱ هفته و حداکثر طول اپیزود بیماری ۲ سال.
شرایط خروج: اختلال افسردگی عمده شدید؛ وجود علائم سایکوتیک؛ اختلالات اضطرابی.
شرایط ورود: بیمار با سن 16 تا 85 سال با اختلال افسردگی عمده و یا دوقطبی در فاز افسردگی
شرایط خروج: وجود علائم سایکوتیک؛ اختلالات اضطرابی.
شرایط ورود: بیمار با سن 16 تا 85 سال با اختلال افسردگی عمده خفیف تا متوسط با حداقل طول اپیزود بیماری ۱ هفته و حداکثر طول اپیزود بیماری ۲ سال.یا دوقطبی در فاز افسردگی شرایط خروج: اختلال افسردگی عمده شدید؛ وجود علائم سایکوتیک؛ اختلالات اضطرابی.
General information
empty
Expanding the range of patients due to the lack of patients to conduct the study
Expanding the range of patients due to the lack of patients to conduct the study
empty
گسترده کردن طیف بیماران به علت کمبود بیمار برای انجام مطالعه
گسترده کردن طیف بیماران به علت کمبود بیمار برای انجام مطالعه
Aged 18 to 65 years
The minimum duration of the disease episode be1 week and the maximum duration of the disease episode be 2 years
Mild to moderate major depressive disorder
Aged 18 to 65 years
A patient with major depressive disorder or bipolar disorder in the depressive episode
Aged 18 to 65 years The minimum duration of the disease episode be1 week and the maximum duration of the disease episode be 2 years Mild to moderateA patient with major depressive disorder or bipolar disorder in the depressive episode
سن ۱۸ تا ۶۵ سال
حداقل طول اپیزود بیماری ۱ هفته و حداکثر طول اپیزود بیماری ۲ سال
اختلال افسردگی عمده خفیف تا متوسط
سن ۱۸ تا ۶۵ سال
بیمار مبتلا به اختلال افسردگی عمده و یا دوقطبی در فاز افسردگی
سن ۱۸ تا ۶۵ سال حداقل طول اپیزود بیماری ۱ هفته و حداکثر طول اپیزود بیماری ۲ سالبیمار مبتلا به اختلال افسردگی عمده خفیف تا متوسطو یا دوقطبی در فاز افسردگی
Severe major depressive disorder
Existence of psychotic symptoms
Cognition disorders
Anxiety disorders
Bipolar
Schizophrenia
Antisocial personality disorder
Mental retardation
Dementia
Pregnancy
Lactation
Explicit suicidal ideation
History of allergy to herbal drugs
Having a proven problem with the sense of smell
Existence of psychotic symptoms
Cognition disorders
Anxiety disorders
Schizophrenia
Antisocial personality disorder
Mental retardation
Dementia
Pregnancy
Lactation
Explicit suicidal ideation
History of allergy to herbal drugs
Having a proven problem with the sense of smell
Severe major depressive disorder Existence of psychotic symptoms Cognition disorders Anxiety disorders Bipolar Schizophrenia Antisocial personality disorder Mental retardation Dementia Pregnancy Lactation Explicit suicidal ideation History of allergy to herbal drugs Having a proven problem with the sense of smell
اختلال افسردگی عمده شدید
وجود علائم سایکوتیک
اختلالات شناختی
اختلالات اضطرابی
وجود اختلال دوقطبی و یا سابقه آن
اسکیزوفرنی
اختلال شخصیت ضداجتماعی
عقب ماندگی ذهنی
زوال عقل
بارداری
شیردهی
افکار خودکشی واضح
سابقه حساسیت به داروهای گیاهی
داشتن مشکل اثبات شده در حس بویایی
وجود علائم سایکوتیک
اختلالات شناختی
اختلالات اضطرابی
اسکیزوفرنی
اختلال شخصیت ضداجتماعی
عقب ماندگی ذهنی
زوال عقل
بارداری
شیردهی
افکار خودکشی واضح
سابقه حساسیت به داروهای گیاهی
داشتن مشکل اثبات شده در حس بویایی
اختلال افسردگی عمده شدید وجود علائم سایکوتیک اختلالات شناختی اختلالات اضطرابی وجود اختلال دوقطبی و یا سابقه آن اسکیزوفرنی اختلال شخصیت ضداجتماعی عقب ماندگی ذهنی زوال عقل بارداری شیردهی افکار خودکشی واضح سابقه حساسیت به داروهای گیاهی داشتن مشکل اثبات شده در حس بویایی
Health conditions studied
#1
empty
F32.2
F32.2
empty
Major depressive disorder, single episode, severe without psychotic features
Major depressive disorder, single episode, severe without psychotic features
empty
Major depressive disorder, single episode, severe without psychotic features
Major depressive disorder, single episode, severe without psychotic features
empty
اختلال افسردگی عمده، تک قسمتی، شدید بدون علائم سایکوتیک
اختلال افسردگی عمده، تک قسمتی، شدید بدون علائم سایکوتیک
#2
empty
F33.2
F33.2
empty
Major depressive disorder, recurrent severe without psychotic features
Major depressive disorder, recurrent severe without psychotic features
empty
Major depressive disorder, recurrent severe without psychotic features
Major depressive disorder, recurrent severe without psychotic features
empty
اختلال افسردگی عمده، عودشونده، شدید بدون علائم سایکوتیک
اختلال افسردگی عمده، عودشونده، شدید بدون علائم سایکوتیک
#3
empty
F31.3
F31.3
empty
Bipolar disorder, current episode depressed, mild or moderate severity
Bipolar disorder, current episode depressed, mild or moderate severity
empty
Bipolar disorder, current episode depressed, mild or moderate severity
Bipolar disorder, current episode depressed, mild or moderate severity
empty
اختلال دوقطبی، اپیزود کنونی افسردگی خفیف تا متوسط
اختلال دوقطبی، اپیزود کنونی افسردگی خفیف تا متوسط
#4
empty
F31.4
F31.4
empty
Bipolar disorder, current episode depressed, severe, without psychotic features
Bipolar disorder, current episode depressed, severe, without psychotic features
empty
Bipolar disorder, current episode depressed, severe, without psychotic features
Bipolar disorder, current episode depressed, severe, without psychotic features
empty
اختلال دوقطبی، اپیزود کنونی افسردگی شدید بدون علائم سایکوتیک
اختلال دوقطبی، اپیزود کنونی افسردگی شدید بدون علائم سایکوتیک
Protocol summary
Study aim
Comparison of changes in the overall score of the Hamilton Depression Inventory and the change in disease severity score and the overall progress score in the General Clinical Statement Questionnaire in patients with major depressive disorder or bipolar disorder in the depressive episode receiving standard treatment with clove and receiving standard treatment with placebo
Design
A randomized clinical trial with a control group, parallel design, triple-blind, phase 3.
Settings and conduct
This clinical trial will be performed in Sina Hospital and Imam Khomeini Clinic in Hamadan. Spray containers containing clove essential oil with cans containing cloves will be identified as X and placebo spray containers with cans containing wheat will be identified as Y and will be provided to the physician. The blind mode will be triple-blind.
Participants/Inclusion and exclusion criteria
Inclusion criteria: A patient aged 16 to 85 years with major depressive disorder or bipolar disorder in the depressive episode;
Exclusion criteria: the existence of psychotic symptoms; Anxiety disorders.
Intervention groups
Intervention group: 2 months of sertraline + inhalation of a puff of 5% clove essential oil per day + placing the container containing the clove next to the pillow at a certain distance during the night
control group: 2 months of sertraline + inhalation of a placebo puff per day + placing the container containing the wheat next to the pillow at a certain distance during the night
Main outcome variables
Score items of the Hamilton Depression Inventory
score of Severity of illness, and Global improvement of Clinical Global Impression Questionnaire
General information
Reason for update
Expanding the range of patients due to the lack of patients to conduct the study
Acronym
IRCT registration information
IRCT registration number:IRCT20211223053499N1
Registration date:2022-01-21, 1400/11/01
Registration timing:prospective
Last update:2023-03-24, 1402/01/04
Update count:1
Registration date
2022-01-21, 1400/11/01
Registrant information
Name
Sara Javan
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 4629 2601
Email address
sarajavan2014@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-01-24, 1400/11/04
Expected recruitment end date
2022-04-24, 1401/02/04
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Phytochemical evaluation and clinical effect of Syzygium aromaticum in comparison with the control group on reducing depression in depressive patients: a triple-blind randomized clinical trial
Public title
The effect of clove in depression
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Aged 18 to 65 years
A patient with major depressive disorder or bipolar disorder in the depressive episode
Exclusion criteria:
Existence of psychotic symptoms
Cognition disorders
Anxiety disorders
Schizophrenia
Antisocial personality disorder
Mental retardation
Dementia
Pregnancy
Lactation
Explicit suicidal ideation
History of allergy to herbal drugs
Having a proven problem with the sense of smell
Age
From 18 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Care provider
Investigator
Outcome assessor
Data analyser
Data and Safety Monitoring Board
Sample size
Target sample size:
70
Randomization (investigator's opinion)
Randomized
Randomization description
For this purpose, we will use the balanced block randomization (block size: 4). We prepare four sheets of paper. On the two sheets we write the ((I)) meaning "Intervention" and on the other two sheets we write the ((P)) meaning "Placebo". Mix the sheets together and place them in the table drawer. With the referral of each eligible patient, one of the sheets was randomly pulled out and based on this sheet, I or P was drawn to one of the two groups of intervention (receiving standard treatment with cloves) or control (receiving Standard treatment with placebo). It should be noted that the pulled out sheets will not be returned to the drawer until all four sheets have been pulled out. After randomly pulling out all four sheets, all the sheets are returned to the drawer and the above operation will be continued for the next four patients until the desired sample size (70 patients) is reached.
Blinding (investigator's opinion)
Triple blinded
Blinding description
Containers containing clove essential oil with dark cans with open lids containing cloves in the form of X and placebo containers with dark cans with open lids containing wheat in the form of Y will be recognized and will be provided to the physician. Only the researcher is aware of the contents of the capsules, the patient's examining physician and the patient himself/herself, will not be aware of any of the contents of the labeled capsules. Therefore, the study design will be triple-blind.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Hamadan University of Medical Sciences
Street address
Hamadan University of Medical Sciences, Martyr Fahmideh Street, Hamadan
City
Hamadan
Province
Hamadan
Postal code
6517838678
Approval date
2021-12-12, 1400/09/21
Ethics committee reference number
IR.UMSHA.REC.1400.715
Health conditions studied
1
Description of health condition studied
Major depressive disorder, single episode, moderate
ICD-10 code
F32.1
ICD-10 code description
Major depressive disorder, single episode, moderate
2
Description of health condition studied
Major depressive disorder, single episode, mild
ICD-10 code
F32.0
ICD-10 code description
Major depressive disorder, single episode, mild
3
Description of health condition studied
Major depressive disorder, recurrent, mild
ICD-10 code
F33.0
ICD-10 code description
Major depressive disorder, recurrent, mild
4
Description of health condition studied
Major depressive disorder, recurrent, moderate
ICD-10 code
F33.1
ICD-10 code description
Major depressive disorder, recurrent, moderate
5
Description of health condition studied
Major depressive disorder, single episode, severe without psychotic features
ICD-10 code
F32.2
ICD-10 code description
Major depressive disorder, single episode, severe without psychotic features
6
Description of health condition studied
Major depressive disorder, recurrent severe without psychotic features
ICD-10 code
F33.2
ICD-10 code description
Major depressive disorder, recurrent severe without psychotic features
7
Description of health condition studied
Bipolar disorder, current episode depressed, mild or moderate severity
ICD-10 code
F31.3
ICD-10 code description
Bipolar disorder, current episode depressed, mild or moderate severity
8
Description of health condition studied
Bipolar disorder, current episode depressed, severe, without psychotic features
ICD-10 code
F31.4
ICD-10 code description
Bipolar disorder, current episode depressed, severe, without psychotic features
Primary outcomes
1
Description
Depression rate
Timepoint
Weeks 0, 4 and 8 after the start of the intervention
Method of measurement
Hamilton Depression Inventory 17 items and Clinical Global Impression Questionnaire
Secondary outcomes
empty
Intervention groups
1
Description
Intervention group: 2 months of standard treatment (sertraline) + inhalation of one puff per day of 5% clove essential oil (diluted in ethanol) applied to the collar of the shirt + placing the container containing the clove next to the pillow at a certain distance during the night. Merck ethanol. Essential oil prepared in the pharmacognosy laboratory of Hamadan University of Medical Sciences.
Category
Treatment - Drugs
2
Description
Control group: 2 months of standard treatment (sertraline) + inhalation of a puff per day placebo (ethanol) applied to the collar of the shirt + placing the container containing wheat next to the pillow at a certain distance during the night. Merck ethanol.
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Sina Hospital
Full name of responsible person
Dara Dastan
Street address
Mirzade Eshghi
City
Hamadan
Province
Hamadan
Postal code
6516848741
Phone
+98 81 3827 4184
Email
dara962@gmail.com
2
Recruitment center
Name of recruitment center
Iman Khomeini clinic
Full name of responsible person
Dara Dastan
Street address
Mirzade Eshghi
City
Hamadan
Province
Hamadan
Postal code
6516848741
Phone
+98 81 3832 1460
Email
dara962@gmail.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
دکتر رضا شکوهی
Street address
Fahmideh
City
Hamadan
Province
Hamadan
Postal code
6517838678
Phone
+98 81 3838 0717
Fax
Email
info.research@umsha.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Hamedan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
Sara Javan
Position
university student
Latest degree
A Level or less
Other areas of specialty/work
Medical Pharmacy
Street address
Fahmideh
City
Hamadan
Province
Hamadan
Postal code
6517838695
Phone
+98 81 3838 0548
Email
sarajavan2014@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
Dara Dastan
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Phytochemistry
Street address
فهمیده
City
Hamadan
Province
Hamadan
Postal code
6517838695
Phone
+98 81 3838 0548
Email
dara962@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Hamedan University of Medical Sciences
Full name of responsible person
Sara Javan
Position
university student
Latest degree
A Level or less
Other areas of specialty/work
Medical Pharmacy
Street address
Fahmideh
City
Hamadan
Province
Hamadan
Postal code
6517838695
Phone
+98 21 4629 2601
Email
sarajavan2014@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available